...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
AGORACOM NEWS FLASH

BREAKING: Mota Ventures Signs Letter of Intent for Merger with Stillcanna

  • Stillcanna looks to become one of the largest producers of THC-free CBD extracts in Europe
  • Stillcanna's Polish extraction facility, NEXUS, features industrial-scale centrifugal chromatography equipment that allows for the production of bulk THC-free CBD distillate as well as custom Cannabinoid profiles
  • In February 2020, Stillcanna's Romanian extraction facility, ORIGIN, which operates pursuant to a joint venture between Stillcanna and Dragonfly Biosciences Ltd., received approval from the Ministry of Health and the Anti-Drug Agency to become the first government recognized extraction facility in the country
  • To date C$23,000,000 has been invested by Stillcanna in the cultivation and extraction operations,
  • Current cash on hand in Stillcanna of approximately C$7,000,000
  • Stillcanna's CBD extracts are key to unlocking additional value in Mota's retail offerings in Europe
  • Shareholders of Stillcanna would receive one common share of Mota for every 1.8 common shares of Stillcanna held at the time of exchange

Mota large

Hub On AGORACOM / Read Release

 

Message: Future Trials

BDZ - I understand that more robust trials will be necessary to confirm the results of the CKD and Cognition sub-studies.  However, I’m unclear as to the need for one on CVD.  BoM focused on 3 pt. MACE that included stroke with ABL having demonstrated no impact on stroke.  When substituting CHF for stroke the BoM trial would have achieved statistical significance.

So, why do another trial that would substitute stroke with CHF when we already know the result?  Further, when planning another CVD trial, whether it’s called a bolt-on or something else, what would that trial (in your opinion) look like?

Apologies in advance for my scientific ignorance.....and thanks.

Share
New Message
Please login to post a reply